

AngioDynamics' CEO Eamonn Hobbs Elected to MDMA Board of Directors

QUEENSBURY, N.Y.--(BUSINESS WIRE)--May 31, 2005--AngioDynamics, Inc. (NASDAQ:ANGO) today announced that Eamonn Hobbs, president and chief executive officer, was elected to the Medical Device Manufacturers Association (MDMA) Board of Directors at their 11th Annual Meeting held in Washington, D.C. on May 17th and 18th of 2005.

MDMA is a national trade association based in Washington, D.C. that represents independent manufacturers of medical devices, diagnostic products, and health care information systems. MDMA's mission is to promote public health and improve patient care through advocacy of innovative, research-driven medical device technology.

"We are pleased to welcome Eamonn Hobbs to the MDMA Board. His knowledge and expertise in the medical technology sector as well as his unique insight and perspective will serve to better MDMA," said Mark Leahey, Executive Director of MDMA.

"I am privileged to serve on the MDMA Board of Directors," said Eamonn Hobbs. "I look forward to contributing to and supporting the advancement of medical device technology through this important organization. The representation that MDMA gives to the medical device technology companies in the United States Congress and other various agencies in our Nation's Capital is critical to our industry."

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the outcome of the Diomed patent litigation, the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended November 27, 2004, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.
Robert Rossell, 800-772-6446 x112
<http://www.angiodynamics.com/>
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
212-838-3777
Bruce Voss (bvoss@lhai.com)
310-691-7100

SOURCE: AngioDynamics, Inc.